接受丁丙诺啡治疗阿片类使用障碍者中兴奋剂处方与药物相关中毒风险分析
这项回顾性、复发事件队列研究采用病例交叉设计,二次分析IBM MarketScan商业保险和多州医疗补助数据库2006年1月1日至2016年12月31日的数据,纳入22 946例有阿片类使用障碍诊断、接受丁丙诺啡处方且至少经历1次药物相关中毒的12至64岁个体,观察单位为人日。结果显示,兴奋剂治疗日与药物相关中毒风险增加19%相关(OR 1.19,95%CI 1.06-1.34),丁丙诺啡治疗日与中毒风险降低38%相关(OR 0.62,95%CI 0.59-0.65),两者无显著交互作用。兴奋剂治疗日与丁丙诺啡治疗脱失风险降低相关(OR 0.64,95%CI 0.59-0.70),提示兴奋剂使用与丁丙诺啡平均暴露时间延长36%及其伴随保护相关。作者认为,兴奋剂处方与每日药物相关中毒风险轻度增加相关,但这一风险被兴奋剂使用与丁丙诺啡治疗保留改善之间的关联所抵消。
要点
- 在22 946例接受丁丙诺啡治疗的阿片类使用障碍者中,兴奋剂治疗日与药物相关中毒风险增加19%相关(OR 1.19,95%CI 1.06-1.34)。
- 丁丙诺啡治疗日与药物相关中毒风险降低38%相关(OR 0.62,95%CI 0.59-0.65)。
- 兴奋剂使用与丁丙诺啡之间无显著交互作用。
- 兴奋剂治疗日与丁丙诺啡治疗脱失风险降低相关(OR 0.64,95%CI 0.59-0.70),提示与丁丙诺啡平均暴露时间延长36%相关。
适用人群与场景
- 12至64岁、有阿片类使用障碍诊断并接受丁丙诺啡处方、且至少经历1次药物相关中毒的个体。
- 数据来源为IBM MarketScan商业保险和多州医疗补助数据库2006年1月1日至2016年12月31日的行政索赔数据。
诊断标准与关键阈值
- 药物相关中毒:使用国际疾病分类第九版(ICD-9)和国际疾病统计分类第十版(ICD-10)编码定义。
- 丁丙诺啡治疗保留:定义为持续治疗索赔直至观察到45天间隔。
研究设计与关键结果
- 研究类型:回顾性、复发事件队列研究,采用病例交叉设计,为行政索赔数据的二次分析;共纳入22 946例个体,观察时间13 778 567人日;平均(标准差)年龄32.8(11.8)岁,50.3%为男性。
- 主要终点:兴奋剂治疗日与药物相关中毒风险增加19%相关(OR 1.19,95%CI 1.06-1.34),对照为非治疗日;丁丙诺啡治疗日与药物相关中毒风险降低38%相关(OR 0.62,95%CI 0.59-0.65)。
- 兴奋剂使用与丁丙诺啡之间无显著交互作用。
- 关键次要终点:兴奋剂治疗日与丁丙诺啡治疗脱失风险降低相关(OR 0.64,95%CI 0.59-0.70),提示兴奋剂使用与丁丙诺啡平均暴露时间延长36%及其伴随保护相关。
证据类型、等级与局限
- 证据类型:回顾性、复发事件队列研究,采用病例交叉设计,为行政索赔数据的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在阿片类使用障碍者中,兴奋剂处方使用与每日药物相关中毒风险轻度增加相关,但这一风险被兴奋剂使用与丁丙诺啡治疗保留改善之间的关联所抵消,后者与过量保护相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Stimulant medication use is common among individuals receiving buprenorphine for opioid use disorder (OUD). Associations between prescription stimulant use and treatment outcomes in this population have been understudied.
OBJECTIVES: To investigate whether use of prescription stimulants was associated with (1) drug-related poisoning and (2) buprenorphine treatment retention.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective, recurrent-event cohort study with a case-crossover design used a secondary analysis of administrative claims data from IBM MarketScan Commercial and Multi-State Medicaid databases from January 1, 2006, to December 31, 2016. Primary analyses were conducted from March 1 through August 31, 2021. Individuals aged 12 to 64 years with an OUD diagnosis and prescribed buprenorphine who experienced at least 1 drug-related poisoning were included in the analysis. Unit of observation was the person-day.
EXPOSURES: Days of active stimulant prescriptions.
MAIN OUTCOMES AND MEASURES: Primary outcomes were drug-related poisoning and buprenorphine treatment retention. Drug-related poisonings were defined using International Classification of Diseases, Ninth Revision, and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, codes; treatment retention was defined by continuous treatment claims until a 45-day gap was observed.
RESULTS: There were 13 778 567 person-days of observation time among 22 946 individuals (mean [SD] age, 32.8 [11.8] years; 50.3% men) who experienced a drug-related poisoning. Stimulant treatment days were associated with 19% increased odds of drug-related poisoning (odds ratio [OR], 1.19 [95% CI, 1.06-1.34]) compared with nontreatment days; buprenorphine treatment days were associated with 38% decreased odds of poisoning (OR, 0.62 [95% CI, 0.59-0.65]). There were no significant interaction effects between use of stimulants and buprenorphine. Stimulant treatment days were associated with decreased odds of attrition from buprenorphine treatment (OR, 0.64 [95% CI, 0.59-0.70]), indicating that stimulants were associated with 36% longer mean exposure to buprenorphine and its concomitant protection.
CONCLUSIONS AND RELEVANCE: Among persons with OUD, use of prescription stimulants was associated with a modest increase in per-day risk of drug-related poisoning, but this risk was offset by the association between stimulant use and improved retention to buprenorphine treatment, which is associated with protection against overdose.
参考来源
- Mintz CM, Xu KY, Presnall NJ, et al. Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder. JAMA Netw Open. 2022. PMID: 35544135. doi:10.1001/jamanetworkopen.2022.11634
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。